Severe Arboviral Neuroinvasive Disease in Patients on Rituximab Therapy: A Review

With increasing use of rituximab and other B-cell depleting monoclonal antibodies for multiple indications, infectious complications are being recognized. We summarize clinical findings of patients on rituximab with arboviral diseases identified through literature review or consultation with the Cen...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Clinical infectious diseases Ročník 76; číslo 6; s. 1142
Hlavní autoři: Kapadia, Ronak K, Staples, J Erin, Gill, Christine M, Fischer, Marc, Khan, Ezza, Laven, Janeen J, Panella, Amanda, Velez, Jason O, Hughes, Holly R, Brault, Aaron, Pastula, Daniel M, Gould, Carolyn V
Médium: Journal Article
Jazyk:angličtina
Vydáno: United States 21.03.2023
Témata:
Animals
Arbovirus Infections
Disease Outbreaks
Encephalitis, Tick-Borne - epidemiology
Rituximab - therapeutic use
West Nile Fever - complications
West Nile Fever - drug therapy
West Nile Fever - epidemiology
anti-CD20
arboviral disease
rituximab
arbovirus
monoclonal antibodies
ISSN:1537-6591, 1537-6591
On-line přístup:Zjistit podrobnosti o přístupu
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:With increasing use of rituximab and other B-cell depleting monoclonal antibodies for multiple indications, infectious complications are being recognized. We summarize clinical findings of patients on rituximab with arboviral diseases identified through literature review or consultation with the Centers for Disease Control and Prevention. We identified 21 patients on recent rituximab therapy who were diagnosed with an arboviral disease caused by West Nile, tick-borne encephalitis, eastern equine encephalitis, Cache Valley, Jamestown Canyon, and Powassan viruses. All reported patients had neuroinvasive disease. The diagnosis of arboviral infection required molecular testing in 20 (95%) patients. Median illness duration was 36 days (range, 12 days to 1 year), and 15/19 (79%) patients died from their illness. Patients on rituximab with arboviral disease can have a severe or prolonged course with an absence of serologic response. Patients should be counseled about mosquito and tick bite prevention when receiving rituximab and other B-cell depleting therapies.
Bibliografie:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:1537-6591
1537-6591
DOI:10.1093/cid/ciac766